KALA insider trading
NasdaqCM HealthcareKALA BIO, Inc.: insider trade history from SEC Form 4 filings.
About KALA BIO, Inc.
KALA BIO, Inc. a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare and severe eye diseases. The company's lead product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; and limbal stem cell deficiency and other rare corneal diseases. Its preclinical development product consists of KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.
Company website: www.kalarx.com
KALA insider activity at a glance
FilingIQ tracks 250 insider transactions for KALA in filings since Jul 20, 2017. The most recent transaction is dated Oct 23, 2025.
Across the full history, 34 open-market purchases
and 80 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on KALA insider trades is 58.9/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest KALA Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for KALA?
- FilingIQ tracks 250 Form 4 insider transactions for KALA (KALA BIO, Inc.), covering filings from Jul 20, 2017 onwards. 0 of those are dated within the last 90 days.
- Are KALA insiders net buyers or net sellers?
- Across the full Form 4 history for KALA, 34 transactions (14%) were open-market purchases and 80 (32%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does KALA insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is KALA in?
- KALA BIO, Inc. (KALA) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $346.85M.
Methodology & sources
Every KALA insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.